Investor Presentaiton

CASE STUDIES: INVESTMENT PROJECTS IN 2018-2019 AEB Novo Nordisk LLC 19 CENTRA is Kampas How Зид SARY CEO Lars Fruergaard Jorgensen Date of the investment project 2015 Opening of the Factory. 19 September 2018 - Launch of full cycle production (filling & formulation, except API), opening of the new FlexPen Assembly line. Amount of investments More than 8 bln RUR Location Kaluga region, Technopark "Grabtsevo" Brief information about the investment project Novo Nordisk plant since it's opening in 2015 has been an example of com- pany's successful investment in localization of manufacturing and Russian pharmaceutical industry modernization. Novo Nordisk production site com- plies with GMP standards, corporate standards and Russian pharmaceuti- cal regulation, advanced solutions in energy efficiency and environmental protection are applied at Novo Nordisk plant as well. More than 8 bln RUR were invested in the development of production site, about 300 jobs were created, total production area covers 13,000 m². High-tech Novo Nordisk plant in Russia produces on a full cycle basis modern insulin, which have no analogues in Russia.³ The plant uses the original API produced at the company's sites in Denmark. Production operations in Russia include aseptic production, formulation and filling of ready-made dosage forms in cartridg- es, as well as assembly and packaging of FlexPenⓇ pre-filled multidosage disposable pens. Association of European Businesses 60

View entire presentation